MMulti-Immune HR

A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)

More Information

Trial Status
Not yet accepting
Trial Phase
Phase 2
Enrollment
50 patients (estimated)
Sponsors
University of Arkansas for Medical Sciences (UAMS)
Collaborators
Johnson & Johnson
Tags
Bispecific Antibody, B-Cell Maturation Antigen (BCMA), GPRC5D, Minimal Residual Disease (MRD)
Trial Type
Treatment
Last Update
2 weeks ago
SparkCures ID
2134
NCT Identifier
NCT07029776

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.